NICE-SUGAR: the end of a sweet dream?
AUTOR(ES)
Preiser, Jean-Charles
FONTE
BioMed Central
RESUMO
The results of the NICE-SUGAR (Normoglycaemia in Intensive Care Evaluation Survival Using Glucose Algorithm Regulation) trial were released last March. The primary outcome variable, 90-day mortality, was actually increased in patients randomly assigned to intensive insulin therapy, as compared with an intermediate target range for blood glucose. These findings, reflecting data collected in a set of more than 6,000 patients, clearly refute the external validity of tight glucose control. Future research will probably focus on several questions raised by the divergent results reported from investigations in the field of glucose control in the critically ill.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2717409Documentos Relacionados
- Confocal laser endomicroscopy in inflammatory bowel diseases: future, reality or dream?
- The worst accident in the world—Chernobyl; the end of the nuclear dream
- NICE guidance has failed to end “postcode prescribing”
- Sugar and Alcohol Stabilization of Yeast in Sweet Wine
- When sugar is not so sweet: glucose toxicity.